Concurrent chemotherapy

Phase 3

Concurrent chemotherapy is one of 8 therapeutic programs targeting NSCLC (Non-small Cell Lung Cancer). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NSCLC (non-Small Cell Lung Cancer)Recruiting

Locally Advanced Rectal AdenocarcinomaRecruiting

Cervival CancerRecruiting

NSCLC (non-Small Cell Lung Cancer)Phase 2

Recruiting

Locally Advanced Rectal AdenocarcinomaPhase 2

Recruiting

Cervival CancerPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in NSCLC (non-Small Cell Lung Cancer)

#DrugCompanyPhaseTrials

Gavreto

RRigel Pharmaceuticals

Approved

1 2

Beyfortus

BeiGene

Phase 2

1 3

PD-1/PD-L1 Inhibitor

SSecond Affiliated Hospital of Soochow University

Phase 3

1 4

Concurrent chemotherapy

SSun Yat-sen University

Phase 3

1 5

Surufatinib

HHutchison Medipharma Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalNot yet recruiting

Non Muscle Invasive Bladder Cancer

NCT07873333

Phase 2Recruiting

Locally Advanced Rectal Adenocarcinoma

NCT07200141

Q2 2029

Phase 2Recruiting

NSCLC (non-Small Cell Lung Cancer)

NCT07609121

Q4 2029

Phase 2Not yet recruiting

Lung Cancer (NSCLC)

NCT07874464

Q2 2033

Phase 3Recruiting

Cervival Cancer

NCT07709650

Clinical

Trials by Indication[1]

Non Muscle Invasive Bladder Cancer1 trial

Evaluating the Role of Definitive Radiotherapy in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Randamized Controlled Trial (RCT)

Not yet recruiting·AAssiut University·Preclinical·NCT07873333·70 enrolled

Lung Cancer (NSCLC)1 trial

A Prospective Phase II Study to Evaluate Concurrent Radiotherapy Combined With Full-course Immunotherapy or Concurrent Radiotherapy Combined With Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07874464·256 enrolled

Locally Advanced Rectal Adenocarcinoma1 trial

Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer：A Phase 2, Randomized Controlled Study

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07200141·156 enrolled

Unresectable Pancreatic Cancer1 trial

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-metastatic Pancreatic Cancer

Completed·MMedical College of Wisconsin·Phase 2·NCT01972919·23 enrolled

Cervival Cancer1 trial

HYPOfractionated Whole Pelvic Concurrent Chemoradiotherapy in Cervical Cancer (HYPOCx Trial): A Phase III Randomized Controlled Trial

Recruiting·MMahidol University·Phase 3·NCT07709650·250 enrolled

2 more indications

Non-Small Cell Lung Cancer1 trial

A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT06139419·114 enrolled

NSCLC (Non-small Cell Lung Cancer)1 trial

A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT07609121·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Concurrent chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Concurrent chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Concurrent chemotherapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Q4 2029

Q2 2033

Trials by Indication[1]

Non Muscle Invasive Bladder Cancer1 trial

Lung Cancer (NSCLC)1 trial

Locally Advanced Rectal Adenocarcinoma1 trial

Unresectable Pancreatic Cancer1 trial

Cervival Cancer1 trial

Non-Small Cell Lung Cancer1 trial

NSCLC (Non-small Cell Lung Cancer)1 trial

References

Drug Info

Quick Facts

Related News